Curaleaf Secures First Registrations for Standardized Cannabis Preparations in Spain — Curaleaf Holdings, Inc.

Event summary

Curaleaf received the first registrations for standardized cannabis preparations (THC-dominant and CBD-dominant) in Spain under Royal Decree 903/2025.
The approval allows supply to hospital pharmacies for magistral formulas via medical prescription.
Curaleaf's EU-GMP certified manufacturing facility in Alicante supported this milestone.
Registrations (CAN-1 and CAN-2) mark the first under Spain's new regulatory framework.

The big picture

Curaleaf's achievement underscores its strategic focus on Europe, particularly Spain, as a key market for medicinal cannabis. The registration aligns with broader industry trends toward standardized, pharmaceutical-grade cannabis products and regulatory frameworks that facilitate patient access. With nearly 50 million people in Spain, this milestone could significantly expand Curaleaf's reach in the European medical cannabis sector.

What we're watching

Regulatory Execution: How quickly Spain's healthcare system integrates these standardized preparations into hospital pharmacies.
Market Leadership: Whether Curaleaf can maintain its first-mover advantage in Spain's emerging medicinal cannabis market.
Patient Access: The pace at which patients gain access to these preparations through the regulated system.